Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Manitoba
With
Heart and Stroke Foundation of Canada
Manitoba Harvest
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
BMI: 18.5-40 kg/m2
Systolic blood pressure between 130-160 mmHg
Diastolic blood pressure ≤ 110 mmHg
Ability and willingness to give informed consent to participate in the trial
Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits
Willingness to fast 10-12 hours before blood samples and abstain from alcohol two days prior to blood sampling and BP measurement and abstain from coffee and physical exercise at least 14 and 4 hours before measurement respectively
Negative pregnancy test for women with child-bearing potential
You may not be if
Unable to speak/read in English
Active cardiovascular disease including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attacks, secondary hypertension, type 1 or type 2 diabetes, anemia, abnormal electrolytes, proteinuria, and abnormal liver, kidney or thyroid function
History of cancer or malignancy in the last 5 years, or any metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which could interfere with the results of the study or the safety of the participant
Taking lipid or blood pressure lowering medications or any type of supplements for less than 3 months (Note: all medications or supplements will be permitted if they are on a stable dose for more than 3 months before the start of the study)
Smokers, tobacco/snuff/nicotine users, recreational drug users
Consuming more than 14 alcoholic beverages a week
Any dietary restrictions preventing from consuming the trial treatments
Weight gain or loss greater than 5 kg in the past three months
Exercising \> 15 miles/wk or 4,000 kcal/wk
Known to be pregnant or breast-feeding or planning on becoming pregnant during the trial period
Having clinically significant biochemistry defined as: Sodium: \<134 mmol/l, \>148 mmol/l; fasting glucose: \> 6.1 mmol/L; LDL-C ≥4.9 mmol/L or any other clinically significant abnormality in hematology and/or biochemistry at the investigator's discretion
Clareo Health | Hemp Seed Protein and Bioactive Peptides Consumption for Hypertension
